Novo Nordisk Suspends Development of Insulin Sensitizer

By: Jan Chait

Novo Nordisk has suspended development of ragaglitazar—a drug that has potential for regulating both blood-glucose and lipid levels—after finding urine bladder tumors in one mouse and several rats tested with the drug during preclinical trials.

Current clinical trials have been halted, and planned new clinical trials have been suspended, according to a news release from the company.

"The tumors observed may prove to be specific for the rodent species and in that case, they will be of no relevance to humans," says Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk. "However, we have for patient safety reasons decided to take a precautionary approach and stop the ongoing clinical trials while we investigate the preclinical findings in more detail."

Thomsen says it is too early to tell whether new clinical trials will be initiated. If they are, Thomsen expects a delay of about two years.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.